Impact of antimicrobial dosing regimen on evolution of drug resistance in vivo: Fluconazole and Candida albicans

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 7, 2006, Pages 2374-2383

  Andes, D ^b,c   Forrest, A ^c   Lepak, A ^a,b   Nett, J ^a,b   Marchillo, K ^a,b   Lincoln, L ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ANTIMICROBIAL THERAPY; AREA UNDER THE CURVE; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CELL POPULATION; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG HALF LIFE; FEMALE; FUNGUS GROWTH; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT DURATION;

ANIMALS; ANTIFUNGAL AGENTS; AREA UNDER CURVE; CANDIDA ALBICANS; CANDIDIASIS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, FUNGAL; FEMALE; FLUCONAZOLE; HUMANS; MICE; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; SPECIFIC PATHOGEN-FREE ORGANISMS;

EID: 33745606489     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01053-05     Document Type: Article

References (59)

1. Andes, D., and M. Van Ogtrop. 1999. Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis model. Antimicrob. Agents Chemother. 43:2116-2120.
2. Andes, D. 2003. In-vivo pharmacodynamics of antifungal drugs in treatment of candidiasis. Antimicrob. Agents Chemother. 47:1179-1186.
3. Baddley, J. W., and S. A. Moser. 2004. Emerging fungal resistance. Clin. Lab. Med. 24:721-735.
4. Barchiesi, F., D. Calabrese, D. Sanglard, L. DiFancesco, F. Caselli, D. Giannini, A. Giacometti, S. Gavaudan, and G. Scalise. 2000. Experimental induction of fluconazole resistance in Candida tropicalis ATCC 750. Antimicrob. Agents Chemother. 44:1578-1584.
5. Beckerman, J., H. Chibana, J. Turner, and P. T. Magee. 2001. Single-copy IMH3 allele is sufficient to confer resistance to mycophenolic acid in Candida albicans and to mediate transformation of clinical Candida species. Infect. Immun. 69:108-114.
6. Bergstrom, C. T., L. Monique, and M. Lipsitch. 2005. Ecological theory suggests that antimicrobial cycling will not reduce antimicrobial resistance in hospitals. Proc. Natl. Acad. Sci. USA 101:13285-13290.
7. Blaser, J., B. B. Stone, M. C. Groner, and S. H. Zinner. 1987. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob. Agents Chemother. 31:1054-1060.
8. Bonhoeffer, S., M. Lipsitch, and B. R. Levin. 1997. Evaluating treatment protocols to prevent antibiotic resistance. Proc. Natl. Acad. Sci. USA 94:12106-12111.
9. Bouma, J. E., and R. E. Lenski. 1988. Evolution of a bacteria/plasmid association. Nature 335:351-352.
10. Brown, E. M., and D. Nathwani. 2005. Antibiotic cycling or rotation: a systematic review of the evidence of efficacy. J. Antimicrob. Chemother. 55:6-9.
11. Calvet, H. M., M. R. Yeaman, and S. G. Filler. 1997. Reversible fluconazole resistance in Candida albicans: a potential in vitro model. Antimicrob. Agents Chemother. 41:535-539.
12. Cohen, T., B. Sommers, and M. Murray. 2003. The effect of drug resistance on the fitness of Mycobacterium tuberculosis. Lancet Infect. Dis. 3:13-21.
13. Drusano, G. L., D. E. Johnson, M. Rosen, and H. C. Standiford. 1993. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob. Agents Chemother. 37:483-490.
14. Fan-Harvard, P., D. Capano, S. M. Smith, A. Mangia, and R. H. K. Eng. 1991. Development of resistance in Candida isolates from patients receiving prolonged antifungal therapy. Antimicrob. Agents Chemother. 35:2302-2305.
15. Firsov, A. A., S. N. Vostrov, I. Y. Lubenko, K. Drlica, Y. A. Portnoy, and S. H. Zinner. 2003. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob. Agents Chemother. 47:1604-1613.
16. Fish, D. N., S. C. Piscitelli, and L. H. Danziger. 1995. Development of resistance during antimicrobial therapy: a review of antibiotic classes and patient characteristics in 173 studies. Pharmacotherapy 15:279-291.
17. Franz, R., S. L. Kelly, D. C. Lamb, D. E. Kelly, M. Ruhnke, and J. Morschhauser. 1998. Multiple molecular mechanisms contribute to a step-wise development of fluconazole resistance in clinical Candida albicans strains. Antimicrob. Agents Chemother. 42:3065-3072.
18. Gerber, A. U., A. P. Vastola, J. Brandel, and W. A. Craig. 1982. Selection of aminoglycoside-resistant variants of Pseudomonas aeruginosa in an in vivo model. J. Infect. Dis. 146:691-697.
19. Gietz, R. D., and R. A. Woods. 2002. Transformation of yeast by lithium acetate/single-stranded carrier DNA/polyethylene glycol method. Methods Enzymol. 350:87-96.
20. Goetz, M. D. 1996. Relationship between fluconazole dosing regimens and the emergence of fluconazole-resistant Candida albicans. AIDS 10:335-336.
21. Gould, I. M. 2002. Antibiotic policies and control of resistance. Curr. Opin. Infect. Dis. 15:395-400.
22. Hall, B. G. 2004. Predicting the evolution of antibiotic resistance genes. Nat. Rev. Microbiol. 2:430-435.
23. Hernaez, M. L., C. Gil, J. Pla, and C. Nombela. 1998. Induced expression of the Candida albicans multidrug resistance gene CDR1 in response to fluconazole and other antifungals. Yeast 14:517-526.
24. Hoyer, L. L., B. B. Magee, E. H. Rikkerink, and S. Scherer. 1994. The ARG4 gene of Candida albicans. Gene 142:213-218.
25. Jumbe, N., A. Louie, R. Leary, W. Liu, M. R. Deziel, V. H. Tam, R. Bachhawat, C. Freeman, J. B. Kahn, K. Bush, M. N. Dudley, M. H. Miller, and G. L. Drusano. 2003. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J. Clin. Investig. 112:275-285.
26. Kaatz, G. W., S. M. Seo, S. L. Barriere, L. M. Albrecht, and M. J. Rybak. 1991. Development of resistance to fleroxacin during therapy of experimental methicillin-susceptible Staphylococcus aureus endocarditis. Antimicrob. Agents Chemother. 35:1547-1550.
27. Kohler, G. A., T. C. White, and N. Agabian. 1997. Overexpression of a cloned IMP dehydrogenase gene of Candida albicans confers resistance to the specific inhibitor mycophenolic acid. J. Bacteriol. 179:2331-2338.
28. Korting, H. C., H. Behrendt, K. H. Roth, and U. Neubert. 1984. Repeated exposition to subinhibitory concentrations of antibiotics in vitro readily decreases susceptibility of Neisseria gonorrhoeae to rifampicin, but not to new cephalosporins. Chemotherapy 30:366-372.
29. Levy, S. B., and B. Marshall. 2004. Antibacterial resistance worldwide: causes, challenges and responses. Nat. Med. 10(12 Suppl.):S122-S129.
30. Lipsitch, M., and B. R. Levin. 1997. The population dynamics of antimicrobial chemotherapy. Antimicrob. Agents Chemother. 41:363-373.
31. Lipsitch, M., C. T. Bergstrom, and B. R. Levin. 2000. The epidemiology of antibiotic resistance in hospitals: paradoxes and prescriptions. Proc. Natl. Acad. Sci. USA 97:1938-1943.
32. Lopez-Ribot, J. L., R. K. McAtee, L. N. Lee, W. R. Kirkpatrick, T. C. White, D. Sanglard, and T. F. Patterson. 1998. Distinct patterns of gene expression associated with development of fluconazole resistance in serial Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob. Agents Chemother. 42:2932-2937.
33. Lopez-Ribot, J. L., R. K. McAtee, S. Perea, W. R. Kirkpatrick, M. G. Rinaldi, and T. F. Patterson. 1999. Multiple resistant phenotypes of Candida albicans coexist during episodes of oropharyngeal candidiasis in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 43:1621-1630.
34. Marr, K. A., C. N. Lyons, K. Ha, T. R. Rustad, and T. C. White. 2001. Inducible azole resistance associated with a heterogeneous phenotype in Candida albicans. Antimicrob. Agents Chemother. 45:52-59.
35. Marr, K. A., C. N. Lyons, T. R. Rustad, R. A. Bowden, and T. C. White. 1998. Rapid, transient fluconazole resistance in Candida albicans is associated with increased mRNA levels of CDR. Antimicrob. Agents Chemother. 42:2584-2589.
36. Marr, K. A., T. C. White, J. A. H. van Burik, and R. A. Bowden. 1997. Development of fluconazole resistance in Candida albicans causing disseminated infection in a patient undergoing marrow transplantation. Clin. Infect. Dis. 25:908-910.
37. Martinez, J. L., and F. Baquero. 2000. Mutation frequencies and antibiotic resistance. Antimicrob. Agents Chemother. 44:1771-1777.
38. Martinez, J. L., and F. Baquero. 2002. Interactions among strategies associated with bacterial infection: pathogenicity, epidemicity, and antibiotic resistance. Clin. Microbiol. Rev. 15:647-679.
39. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
40. Nolte, F. S., T. Parkinson, D. J. Falconer, S. Dix, J. Williams, C. Gilmore, R. Geller, and J. R. Wingard. 1997. Isolation and characterization of fluconazole and amphotericin B resistant Candida albicans from blood of two patients with leukemia. Antimicrob. Agents Chemother. 41:196-199.
41. Pappas, P. G., J. H. Rex, J. D. Sobel, S. G. Filler, W. E. Dismukes, T. J. Walsh, J. E. Edwards, and Infectious Diseases Society of America. 2004. Guidelines for treatment of candidiasis. Clin. Infect. Dis. 38:161-189.
42. Paterson, D. L. 2003. Restrictive antibiotic policies are appropriate in intensive care units. Crit. Care Med. 31(1 Suppl.):S25-S28.
43. Patterson, T. F., S. G. Revankar, W. R. Kirkpatrick, O. Dib, A. W. Fothergill, S. W. Redding, D. A. Sutton, and M. G. Rinaldi. 1996. A simple method for detecting fluconazole-resistant yeasts with chromogenic agar. J. Clin. Microbiol. 34:1794-1797.
44. Perea, S., and T. F. Patterson. 2002. Antifungal resistance in pathogenic fungi. Clin. Infect. Dis. 35:1073-1080.
45. Pfaller, M. A., and D. J. Diekema. 2004. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J. Clin. Microbiol. 42:4419-4431.
46. Prasad, R., W. P. De, A. Goffeau, and E. Balzi. 1995. Molecular cloning and characterization of a novel gene of Candida albicans, CDR1, conferring multiple resistance to drugs and antifungals. Curr. Genet. 27:320-329.
47. Pujol, C., M. Pfaller, and D. R. Soll. 2002. Ca3 fingerprinting of Candida albicans bloodstream isolates from the United States, Canada, South America, and Europe reveals a European clade. J. Clin. Microbiol. 40:2729-2740.
48. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
49. Sanglard, D., R. Ischer, M. Monod, and J. Bille. 1997. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter. Microbiology 143(Pt 2):405-416.
50. Sanglard, D., K. Kuchler, F. Ischer, J. L. Pagani, M. Monod, and J. Bille. 1995. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob. Agents Chemother. 39:2378-2386.
51. Sanglard, D., F. Ischer, L. Koymans, and J. Bille. 1998. Amino acid substitutions in the cytochrome P-450 lanosterol 14α -demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob. Agents Chemother. 42:241-253.
52. Schmid, J., E. Voss, and D. R. Soll. 1990. Computer-assisted methods for assessing strain relatedness in Candida albicans by fingerprinting with the moderately repetitive sequence Ca3. J. Clin. Microbiol. 28:1236-1243.
53. Selkon, J. B., S. Devadatta, K. G. Kulkarni, D. A. Mitchison, A. S. L. Narayana, C. Narayanan Nair, and K. Ramachandran. 1964. The emergence of isoniazid-resistant cultures in patients with pulmonary tuberculosis during treatment with isoniazid alone or isoniazid plus PAS. Bull. W. H. O. 31:273-294.
54. Sheehan, D. J., C. A. Hitchcock, and C. M. Sibley. 1999. Current and emerging azole antifungal agents. Clin. Microbiol. Rev. 12:40-79.
55. Smith, S. V., and I. M. Gould. 2004. Optimization of antibiotic dosing schedules in the light of increasing antibiotic resistance. Expert Rev. Antiinfect. Ther. 2:227-234.
56. Tumbarello, M., G. Caldarola, E. Tacconelli, G. Morace, B. Posteraro, R. Cauda, and L. Ortona. 1996. Analysis of risk factors associated with the emergence of azole resistant oral candidosis in the course of HIV infection. J. Antimicrob. Chemother. 38:691-699.
57. White, T. C. 1997. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 41:1482-1487.
58. White, T. C., K. A. Marr, and R. A. Bowden. 1998. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin. Microbiol. Rev. 11:382-402.
59. White, T. C., M. A. Pfaller, R. G. Rinaldi, J. Smith, and S. W. Redding. 1997. Stable azole drug resistance associated with a substrain of Candida albicans from an HIV-infected patient. Oral Dis. 3(Suppl. 1):102-109.